Evidence map›Paper›PMID 37431849›Full record

ReviewJournal of comparative effectiveness research2023

Challenges in conducting fractional polynomial and standard parametric network meta-analyses of immune checkpoint inhibitors for first-line advanced renal cell carcinoma.

Svenja Petersohn, Bradley McGregor, Sven L Klijn, Jessica R May, Flavia Ejzykowicz, Murat Kurt, Matthew Dyer, Bill Malcolm, Sébastien Branchoux, Katharina Nickel and 2 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of comparative effectiveness research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Svenja PetersohnOPEN Health Evidence & Access, Marten Meesweg 107, 3068 AV Rotterdam, The Netherlands.ORCID 0000-0001-5058-7645
Bradley McGregorThe Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute, 450 Brookline Ave, Boston, MA 02215, USA.
Sven L KlijnBristol Myers Squibb, Sanderson Rd, Denham, Uxbridge UB8 1DH, UK.
Jessica R MayBristol Myers Squibb, Sanderson Rd, Denham, Uxbridge UB8 1DH, UK.
Flavia EjzykowiczBristol Myers Squibb, 100 Nassau Park Blvd #300, Princeton, NJ 08540, USA.
Murat KurtBristol Myers Squibb, 100 Nassau Park Blvd #300, Princeton, NJ 08540, USA.
Matthew DyerBristol Myers Squibb, Sanderson Rd, Denham, Uxbridge UB8 1DH, UK.
Bill MalcolmBristol Myers Squibb, Sanderson Rd, Denham, Uxbridge UB8 1DH, UK.
Sébastien BranchouxBristol Myers Squibb, 3 Rue Joseph Monier, 92506 Rueil-Malmaison, France.
Katharina NickelOPEN Health Evidence & Access, Krausenstraße 8, 10117, Berlin, Germany.
Saby GeorgeRoswell Park Cancer Institute, 665 Elm St, Buffalo, NY 14203, USA.
Sonja KroepOPEN Health Evidence & Access, Marten Meesweg 107, 3068 AV Rotterdam, The Netherlands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Carcinoma, Renal CellKidney NeoplasmsHumansImmune Checkpoint InhibitorsNetwork Meta-Analysis as TopicProtein Kinase InhibitorsImmune Checkpoint InhibitorsProtein Kinase Inhibitorshealth technology assessmentmeta-analysismethodology

Identifiers

PMID37431849
PMCPMC10508301

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.